• Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 17.08
▲ +0.08 (0.47%)

This chart shows the closing price for SNG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Synairgen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNG

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Synairgen in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 17.08.

This chart shows the closing price for SNG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Synairgen. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/12/2021Numis SecuritiesReiterated RatingBuyGBX 990
7/20/2020FinnCapReiterated RatingCorporate
5/26/2020FinnCapReiterated RatingCorporate
5/1/2020FinnCapReiterated RatingCorporate
3/26/2020FinnCapReiterated RatingCorporate
3/18/2020FinnCapReiterated RatingCorporate
9/30/2019FinnCapReiterated RatingCorporate
7/24/2019FinnCapReiterated RatingCorporate
3/14/2019FinnCapReiterated RatingCorporate
2/25/2019FinnCapReiterated RatingCorporate
1/17/2019FinnCapReiterated RatingCorporate
9/26/2018FinnCapReiterated RatingCorporate
6/28/2018FinnCapReiterated RatingCorporate
6/22/2018FinnCapBoost TargetCorporateGBX 35 ➝ GBX 63
3/15/2018FinnCapReiterated RatingCorporateGBX 35
2/7/2018FinnCapReiterated RatingCorporateGBX 35
12/14/2017FinnCapReiterated RatingCorporate
(Data available from 12/10/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/14/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022
  • 7 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Synairgen logo
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Read More

Today's Range

Now: GBX 17.08
Low: 16.26
High: 17.99

50 Day Range

MA: GBX 18.68
Low: 16.15
High: 23.50

52 Week Range

Now: GBX 17.08
Low: 10
High: 214

Volume

256,892 shs

Average Volume

2,148,979 shs

Market Capitalization

£34.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Synairgen?

The following sell-side analysts have issued stock ratings on Synairgen in the last year:
View the latest analyst ratings for SNG.

What is the current price target for Synairgen?

0 Wall Street analysts have set twelve-month price targets for Synairgen in the last year. has the lowest price target set, forecasting a price of £100,000 for Synairgen in the next year.
View the latest price targets for SNG.

What is the current consensus analyst rating for Synairgen?

Synairgen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SNG.

What other companies compete with Synairgen?

How do I contact Synairgen's investor relations team?

Synairgen's physical mailing address is Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom. The company's listed phone number is +44-23-80512800. The official website for Synairgen is www.synairgen.com. Learn More about contacing Synairgen investor relations.